Rebecca Kristeleit

Rebecca Kristeleit

UNVERIFIED PROFILE

Are you Rebecca Kristeleit?   Register this Author

Register author
Rebecca Kristeleit

Rebecca Kristeleit

Publications by authors named "Rebecca Kristeleit"

Are you Rebecca Kristeleit?   Register this Author

37Publications

1062Reads

29Profile Views

Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process.

Int J Gynecol Cancer 2019 Nov 19. Epub 2019 Nov 19.

Department of Women's Cancer, UCL Elizabeth Garrett Anderson Institution for Women's Health, University College London, London, UK

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2019-000630DOI Listing
November 2019

Mainstreamed genetic testing for women with ovarian cancer: first-year experience.

J Med Genet 2019 03 13;56(3):195-198. Epub 2018 Mar 13.

Wessex Clinical Genetics Service, University Hospitals Southampton, Southampton, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jmedgenet-2017-105140DOI Listing
March 2019

Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.

Eur J Cancer 2017 05 6;76:52-59. Epub 2017 Mar 6.

Royal Marsden NHS Foundation Trust, Downs Road, London SM2 5PT, UK; The Institute of Cancer Research, Cotswold Road, London SM2 5NG, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.01.020DOI Listing
May 2017

Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.

Am Soc Clin Oncol Educ Book 2016 ;35:e259-68

From the Department of Medical Oncology, University College London Hospital, London, United Kingdom; UCL Cancer Institute, University College London, London, United Kingdom; Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_159086DOI Listing
January 2017

Homologous recombination deficiency and ovarian cancer.

Eur J Cancer 2016 06 9;60:49-58. Epub 2016 Apr 9.

UCL Cancer Institute, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.03.005DOI Listing
June 2016

Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials.

Cancer 2014 Jan 8;120(2):262-70. Epub 2013 Oct 8.

Department of Experimental Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.28381
Publisher Site
http://dx.doi.org/10.1002/cncr.28381DOI Listing
January 2014

First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors.

Clin Cancer Res 2013 Oct 24;19(19):5494-504. Epub 2013 Sep 24.

Authors' Affiliations: Drug Development Unit, Divisions of Cancer Therapeutics & Clinical Studies, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom; and 4SC AG, Planegg-Martinsried, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0735DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790647PMC
October 2013

A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors.

Clin Cancer Res 2012 May;18(9):2687-94

The Drug Development Unit, Sycamore House, Division of Cancer Therapeutics/Division of Clinical Studies, The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-3165DOI Listing
May 2012

Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.

Nat Rev Clin Oncol 2011 May 5;8(5):302-6. Epub 2011 Apr 5.

Drug Development Unit, Royal Marsden Hospital, Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2011.42DOI Listing
May 2011

Early oncology clinical trial design in the era of molecular-targeted agents.

Future Oncol 2010 Aug;6(8):1339-52

Section of Medicine, The Institute of Cancer Research, Drug Development Unit, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.10.92DOI Listing
August 2010

Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women's cancers.

Epigenomics 2010 Feb;2(1):9-38

Department of Gynecological Oncology, Institute for Women's Health, University College London, 149 Tottenham Court Road, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/epi.09.47DOI Listing
February 2010

Histone deacetylase inhibitors: emerging anticancer therapeutic agents?

Clin Lung Cancer 2005 Sep;7 Suppl 1:S19-30

Institute for Cancer Research and Royal Marsden Hospital, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/clc.2005.s.004DOI Listing
September 2005

Histone modification enzymes: novel targets for cancer drugs.

Expert Opin Emerg Drugs 2004 May;9(1):135-54

Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/eoed.9.1.135.32947DOI Listing
May 2004